UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 829

Sortiert nach

Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?

Expert opinion on drug metabolism & toxicology, 2012-02, Vol.8 (2), p.141-160

2012

Link zum Volltext

Verfügbarkeit prüfen

The synthetic cathinone α-pyrrolidinovalerophenone (α-PVP): pharmacokinetic and pharmacodynamic clinical and forensic aspects

Drug metabolism reviews, 2018-05, Vol.50 (2), p.125-139

2018

Link zum Volltext

Verfügbarkeit prüfen

Preparation of a novel tacrolimus ion sensitive ocular in situ gel and in vivo evaluation of curative effect of immune conjunctivitis

Pharmaceutical development and technology, 2022-04, Vol.27 (4), p.399-405

2022

Link zum Volltext

Verfügbarkeit prüfen

A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects

Expert opinion on investigational drugs, 2023-10, Vol.32 (10), p.959-966

2023

Link zum Volltext

Verfügbarkeit prüfen

KEAP1 and done? Targeting the NRF2 pathway with sulforaphane

Trends in Food Science & Technology, 2017-11, Vol.69 (Pt B), p.257-269

2017

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients

Expert opinion on drug metabolism & toxicology, 2017-12, Vol.13 (12), p.1225-1236

2017

Link zum Volltext

Verfügbarkeit prüfen

Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study

Expert opinion on investigational drugs, 2022-10, Vol.31 (10), p.1125-1132

2022

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese subjects

Expert opinion on investigational drugs, 2022-10, Vol.31 (10), p.1133-1142

2022

Link zum Volltext

Verfügbarkeit prüfen

Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment

Expert opinion on drug metabolism & toxicology, 2019-10, Vol.15 (10), p.813-829

2019

Link zum Volltext

Verfügbarkeit prüfen

Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4

Leukemia & lymphoma, 2019-06, Vol.60 (7), p.1740-1748

2019

Link zum Volltext

Verfügbarkeit prüfen

A phase-I randomized euglycemic clamp study to demonstrate the pharmacokinetic and pharmacodynamic equivalence of an insulin degludec biosimilar (B01411) with the reference product in healthy Chinese volunteers

Expert opinion on investigational drugs, 2023-08, Vol.32 (8), p.773-781

2023

Link zum Volltext

Verfügbarkeit prüfen

Antimalarial treatment in infants

Expert opinion on pharmacotherapy, 2022-10, Vol.23 (15), p.1711-1726

2022

Link zum Volltext

Verfügbarkeit prüfen

A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers

Expert opinion on investigational drugs, 2022-09, Vol.31 (9), p.977-985

2022

Link zum Volltext

Verfügbarkeit prüfen

The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments

Expert opinion on drug metabolism & toxicology, 2018-12, Vol.14 (12), p.1287-1302

2018

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients

Expert opinion on drug metabolism & toxicology, 2019-11, Vol.15 (11), p.881-895

2019

Link zum Volltext

Verfügbarkeit prüfen

Proniosomal gel-derived niosomes: an approach to sustain and improve the ocular delivery of brimonidine tartrate; formulation, in-vitro characterization, and in-vivo pharmacodynamic study

Drug delivery, 2019-01, Vol.26 (1), p.509-521

2019

Link zum Volltext

Verfügbarkeit prüfen

AXS-05: an investigational treatment for Alzheimer's disease-associated agitation

Expert opinion on investigational drugs, 2022-08, Vol.31 (8), p.773-780

2022

Link zum Volltext

Verfügbarkeit prüfen

Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters

Expert opinion on drug metabolism & toxicology, 2018-03, Vol.14 (3), p.275-285

2018

Link zum Volltext

Verfügbarkeit prüfen

The fate of flavonoids after oral administration: a comprehensive overview of its bioavailability

Critical reviews in food science and nutrition, 2022, Vol.62 (22), p.6169-6186

2022

Link zum Volltext

Verfügbarkeit prüfen

Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactions

Expert opinion on drug metabolism & toxicology, 2017-09, Vol.13 (9), p.953-972

2017

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs

Expert opinion on drug delivery, 2021-07, Vol.18 (7), p.891-906

2021

Link zum Volltext

Verfügbarkeit prüfen

Sources, health benefits, and biological properties of zeaxanthin

Trends in Food Science & Technology, 2021-12, Vol.118, p.519-538

2021

Link zum Volltext

Verfügbarkeit prüfen

Assessing the viability of long-acting β2-agonists in paediatric asthma patients: a pharmacokinetic/pharmacodynamic perspective

Expert opinion on drug metabolism & toxicology, 2017-02, Vol.13 (2), p.129-136

2017

Link zum Volltext

Verfügbarkeit prüfen

Model Informed Development of SIM0295 in Patients with Gout and Hyperuricemia and Healthy Volunteers Using a Population Pharmacokinetics/ Pharmacodynamics Approach

Expert opinion on investigational drugs, 2023-05, Vol.32 (5), p.441-450

2023

Link zum Volltext

Verfügbarkeit prüfen

The role of amikacin in the treatment of nontuberculous mycobacterial disease

Expert opinion on pharmacotherapy, 2021-10, Vol.22 (15), p.1961-1974

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 829

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis Journals Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(801)
Mit Volltextzugriff
(376)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?

The synthetic cathinone α-pyrrolidinovalerophenone (α-PVP): pharmacokinetic and pharmacodynamic clinical and forensic aspects

Preparation of a novel tacrolimus ion sensitive ocular in situ gel and in vivo evaluation of curative effect of immune conjunctivitis

A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects

KEAP1 and done? Targeting the NRF2 pathway with sulforaphane

Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients

Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study

Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese subjects

Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment

Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4

A phase-I randomized euglycemic clamp study to demonstrate the pharmacokinetic and pharmacodynamic equivalence of an insulin degludec biosimilar (B01411) with the reference product in healthy Chinese volunteers

Antimalarial treatment in infants

A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers

The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments

Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients

Proniosomal gel-derived niosomes: an approach to sustain and improve the ocular delivery of brimonidine tartrate; formulation, in-vitro characterization, and in-vivo pharmacodynamic study

AXS-05: an investigational treatment for Alzheimer's disease-associated agitation

Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters

The fate of flavonoids after oral administration: a comprehensive overview of its bioavailability

Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactions

Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs

Sources, health benefits, and biological properties of zeaxanthin

Assessing the viability of long-acting β2-agonists in paediatric asthma patients: a pharmacokinetic/pharmacodynamic perspective

Model Informed Development of SIM0295 in Patients with Gout and Hyperuricemia and Healthy Volunteers Using a Population Pharmacokinetics/ Pharmacodynamics Approach

The role of amikacin in the treatment of nontuberculous mycobacterial disease

Aktive Filter

Suchergebnisse filtern